JAK2/IDH-mutant-driven myeloproliferative neoplasm is sensitive to combined targeted inhibition

JAK2/IDH-mutant-driven myeloproliferative neoplasm is sensitive to combined targeted inhibition

Patients with myeloproliferative neoplasms (MPNs) frequently progress to bone marrow failure or acute myeloid leukemia (AML), and mutations in epigenetic regulators such as the metabolic enzyme isocitrate dehydrogenase (IDH) are associated with poor outcomes. Here, we showed that combined expression...

Full description

Bibliographic Details
Main Authors: McKenney, Anna Sophia (Author), Somasundara, Amritha Varshini Hanasoge (Author), Spitzer, Barbara (Author), Intlekofer, Andrew M. (Author), Ahn, Jihae (Author), Shank, Kaitlyn (Author), Rapaport, Franck T. (Author), Patel, Minal A. (Author), Papalexi, Efthymia (Author), Chiu, April (Author), Freinkman, Elizaveta (Author), Akbay, Esra A. (Author), Steadman, Mya (Author), Nagaraja, Raj (Author), Yen, Katharine (Author), Teruya-Feldstein, Julie (Author), Wong, Kwok-Kin (Author), Rampal, Raajit (Author), Levine, Ross L. (Author), Lau, Allison N. (Contributor), Shihadeh, Alan (Contributor), Vander Heiden, Matthew G. (Contributor), Thompson, Craig B. (Contributor), Levine, Ross L (Contributor)
Other Authors: Broad Institute of MIT and Harvard (Contributor), Massachusetts Institute of Technology. Department of Biological Engineering (Contributor), Massachusetts Institute of Technology. Department of Biology (Contributor), Massachusetts Institute of Technology. Department of Mechanical Engineering (Contributor), Sloan School of Management (Contributor), Koch Institute for Integrative Cancer Research at MIT (Contributor)
Format: Article
Language:English
Published: American Society for Clinical Investigation, 2018-07-12T18:13:31Z.
Subjects:
Article
Online Access:Get fulltext

Internet

Get fulltext

Similar Items